Latest Bayer AG Stories
Growers reminded to CARE as part of commitment to environmental stewardship and collaboration with beekeepers for this year's planting season RESEARCH TRIANGLE PARK, N.C., April 21, 2015 /PRNewswire/
New investment represents continued commitment to California Bay Area as the biotech manufacturing center for Bayer BERKELEY, Calif., April 15, 2015 /PRNewswire/ -- Bayer HealthCare
Claritin, the #1 Selling Non-Drowsy Allergy Brand, is the Proud Sponsor of Spring NEW YORK, March 20, 2015 /PRNewswire/ -- Bayer HealthCare, the makers of Claritin(®), the #1 selling non-drowsy
The plastic additives market is projected to register a CAGR of 5.0% between 2014 and 2019 to reach $45.5 billion by 2019.
10th Annual Ag Issues Forum Brings Together Agriculture, Food, Consumer Leaders PHOENIX, Feb. 24, 2015 /PRNewswire/ -- Nourishing the world tomorrow requires innovation today.
WHIPPANY, N.J., Feb. 9, 2015 /PRNewswire/ -- More than 700,000 people suffer heart attacks and 795,000 people have a stroke each year in the United States.
Three UCSF researchers are partnering with Bayer HealthCare in this unique academic-industry collaboration SAN FRANCISCO, Jan.
Multidistrict Litigation For Xarelto Bleeding Lawsuits That Allege Patients Experienced Uncontrollable Bleeding And Other Complications After Taking The Prescription Blood Thinner Has Been Established
A Request To Centralize Xarelto Lawsuits Alleging Xarelto Users Experience Uncontrolled Bleeding Due To Taking The Blood Thinner Is Under Consideration By the U.S.
Treatment of Visual Impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) and Diabetic Macular Edema (DME) are the Second and Third Indications for Eylea(®) in Canada
- An armed gangster.